ZA9710577B - 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists. - Google Patents

2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists.

Info

Publication number
ZA9710577B
ZA9710577B ZA9710577A ZA9710577A ZA9710577B ZA 9710577 B ZA9710577 B ZA 9710577B ZA 9710577 A ZA9710577 A ZA 9710577A ZA 9710577 A ZA9710577 A ZA 9710577A ZA 9710577 B ZA9710577 B ZA 9710577B
Authority
ZA
South Africa
Prior art keywords
imidazolinylaminoindole
alpha
compounds useful
adrenoceptor agonists
adrenoceptor
Prior art date
Application number
ZA9710577A
Other languages
English (en)
Inventor
Raymond Todd Henry
Russell James Sheldon
William Lee Seibel
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of ZA9710577B publication Critical patent/ZA9710577B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9710577A 1996-11-25 1997-11-25 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists. ZA9710577B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3177796P 1996-11-25 1996-11-25

Publications (1)

Publication Number Publication Date
ZA9710577B true ZA9710577B (en) 1998-06-25

Family

ID=21861336

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9710577A ZA9710577B (en) 1996-11-25 1997-11-25 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists.

Country Status (23)

Country Link
US (2) US6162818A (xx)
EP (1) EP0944621B1 (xx)
JP (1) JP2001506981A (xx)
KR (1) KR100395356B1 (xx)
CN (1) CN1092652C (xx)
AR (1) AR013875A1 (xx)
AT (1) ATE275142T1 (xx)
AU (1) AU735767B2 (xx)
BR (1) BR9713542A (xx)
CA (1) CA2271841C (xx)
CO (1) CO4910149A1 (xx)
CZ (1) CZ180599A3 (xx)
DE (1) DE69730516T2 (xx)
ES (1) ES2225998T3 (xx)
HU (1) HUP9904215A3 (xx)
ID (1) ID22812A (xx)
IL (1) IL130024A (xx)
NO (1) NO992470L (xx)
PE (1) PE16299A1 (xx)
SK (1) SK68399A3 (xx)
TR (1) TR199901885T2 (xx)
WO (1) WO1998023610A1 (xx)
ZA (1) ZA9710577B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677321A (en) 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
DE69730516T2 (de) * 1996-11-25 2005-09-01 The Procter & Gamble Company, Cincinnati 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten
US5866579A (en) * 1997-04-11 1999-02-02 Synaptic Pharmaceutical Corporation Imidazole and imidazoline derivatives and uses thereof
EP1196380A2 (en) * 1999-07-15 2002-04-17 NPS Allelix Corp. Indoles and indazoles for the treatment of migraine
WO2001040183A1 (en) * 1999-12-03 2001-06-07 Alcon Universal Ltd. 1-aminoalkyl-1h-indoles for treating glaucoma
US20030166732A1 (en) * 2002-02-27 2003-09-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity
AU2003243709B2 (en) * 2002-06-24 2007-01-18 Schering Corporation Indole derivatives useful as histamine H3 antagonists
US7795280B2 (en) 2002-11-07 2010-09-14 N.V. Organon Indoles useful in the treatment of androgen-receptor related diseases
DE10332473A1 (de) * 2003-07-16 2005-02-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ambroxol für die Behandlung von Epilepsie
TW200602317A (en) 2004-04-23 2006-01-16 Akzo Nobel Nv Novel androgens
TWI435729B (zh) 2005-11-09 2014-05-01 Combinatorx Inc 治療病症之方法，組合物及套組
US8173813B2 (en) * 2007-03-23 2012-05-08 Neuraxon, Inc. Quinolone and tetrahydroquinolone and related compounds having NOS inhibitory activity
US8952011B2 (en) 2008-08-01 2015-02-10 Eye Therapies Llc Compositions and methods for the treatment of nasal conditions
US20100197694A1 (en) * 2008-08-01 2010-08-05 Gerald Horn Compositions and methods for treatment of diseases and conditions with increased vascular permeability
US20110003823A1 (en) * 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
US20100202979A1 (en) * 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of pulmonary diseases and conditions
US8080550B2 (en) 2008-08-01 2011-12-20 Alpha Synergy Development, Inc. Anesthetic compositions and methods of use
US20100203165A1 (en) 2008-08-01 2010-08-12 Gerald Horn Compositions and methods for treatment of disorders or conditions of the eye
US20100196286A1 (en) * 2008-12-01 2010-08-05 Armer Thomas A Inhalation delivery methods and devices
US8555875B2 (en) 2008-12-23 2013-10-15 Map Pharmaceuticals, Inc. Inhalation devices and related methods for administration of sedative hypnotic compounds
US8987270B2 (en) 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
CN107628981B (zh) * 2017-10-31 2019-07-30 威海市妇女儿童医院 一种肉桂酰基吲哚啉化合物及其制备青光眼药物的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
CH632268A5 (de) * 1977-01-14 1982-09-30 Sandoz Ag Verfahren zur herstellung von neuen heterocyclylaminoderivaten.
US4398028A (en) * 1977-01-14 1983-08-09 Sandoz Ltd. Bicyclic heterocyclic amino derivatives
US5091528A (en) * 1990-09-12 1992-02-25 Allergan, Inc. 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US5677321A (en) * 1996-02-29 1997-10-14 Synaptic Pharmaceutical Corporation 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands
DE69730516T2 (de) * 1996-11-25 2005-09-01 The Procter & Gamble Company, Cincinnati 2-imidazolinylaminoindol verbindungen als alpha-2 adrenoceptor agonisten

Also Published As

Publication number Publication date
EP0944621A1 (en) 1999-09-29
AU5438098A (en) 1998-06-22
CA2271841C (en) 2003-07-08
DE69730516T2 (de) 2005-09-01
IL130024A0 (en) 2000-02-29
HUP9904215A3 (en) 2002-01-28
KR100395356B1 (ko) 2003-08-21
PE16299A1 (es) 1999-03-12
US6162818A (en) 2000-12-19
CN1092652C (zh) 2002-10-16
CZ180599A3 (cs) 1999-11-17
BR9713542A (pt) 2000-01-25
US6395764B1 (en) 2002-05-28
AR013875A1 (es) 2001-01-31
ES2225998T3 (es) 2005-03-16
CN1238771A (zh) 1999-12-15
ID22812A (id) 1999-12-09
CO4910149A1 (es) 2000-04-24
ATE275142T1 (de) 2004-09-15
NO992470D0 (no) 1999-05-21
TR199901885T2 (xx) 1999-10-21
JP2001506981A (ja) 2001-05-29
SK68399A3 (en) 2000-07-11
WO1998023610A1 (en) 1998-06-04
CA2271841A1 (en) 1998-06-04
IL130024A (en) 2002-12-01
KR20000069088A (ko) 2000-11-25
AU735767B2 (en) 2001-07-12
DE69730516D1 (de) 2004-10-07
NO992470L (no) 1999-07-26
EP0944621B1 (en) 2004-09-01
HUP9904215A2 (hu) 2000-06-28

Similar Documents

Publication Publication Date Title
ZA9710577B (en) 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists.
ZA989230B (en) Prostaglandin agonists.
ZA200100900B (en) 2-substituted-1-piperidyl benzimidazole compounds as orl1-receptor agonists.
ZA97222B (en) Lubricating compositions.
ZA97223B (en) Lubricating compositions.
ZA967134B (en) Coolant compositions.
ZA9711092B (en) Novel compounds.
HK1022689A1 (en) Novel compounds with analgesic effect.
ZA9710578B (en) Guanidinyl heterocycle compounds useful as Alpha-2 adrenoceptor agonists.
ZA972514B (en) Pro-fragrance compound.
ZA9710579B (en) 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists.
ZA9711567B (en) Compounds.
ZA975861B (en) Bromotiacumicin compounds.
ZA971638B (en) Microbicidal composition.
ZA9710574B (en) 2-imidazolinylaminobenzothiazole compounds useful as alpha-2 adrenoceptor agonists.
EP0668270A3 (fr) Dérivés de 2-imidazoline-5-ones fongicides.
ZA992899B (en) Novel compound.
ZA9710575B (en) Guanidinylamino heterocycle compounds useful as alpha-2 adrenoceptor agonists.
IL130067A0 (en) 2-Imidazolinylaminoindazole compounds useful as alpha-2 adrenoceptor agonists
IL132384A0 (en) 5-(2-Imidazolinylamino) benzimidazole compounds useful as alpha - 2 adrenoceptor agonists
ZA973485B (en) Antimycotic ectoparasiticidal product-external use.
ZA979404B (en) Aspirinate compounds.
AU1345900A (en) Oxazolidinones useful as alpha 1a adrenoceptor antagonists
ZA987973B (en) Compounds useful as antiatherosclerotic agents.
ZA987970B (en) Compounds useful as antiatherosclerotic agents.